Critical Reviews in Therapeutic Drug Carrier Systems最新文献

Treatments for late-stage prostate cancer (CaP) have not been very successful. Frequently, advanced CaP progresses to castration-resistant prostate cancer (CRPC), with 50#37;-70% of patients developing bone metastases. CaP with bone metastasis-associated clinical complications and treatment resistance presents major clinical challenges. Recent advances in the formulation of clinically applicable nanoparticles (NPs) have attracted attention in the fields of medicine and pharmacology with applications to cancer and infectious and neurological diseases. NPs have been rendered biocompatible, pose little to no toxicity to healthy cells and tissues, and are engineered to carry large therapeutic payloads, including chemo- and genetic therapies. Additionally, if required, targeting specificity can be achieved by chemically coupling aptamers, unique peptide ligands, or monoclonal antibodies to the surface of NPs. Encapsulating toxic drugs within NPs and delivering them specifically to their cellular targets overcomes the problem of systemic toxicity. Encapsulating highly labile genetic therapeutics such as RNA within NPs provides a protective environment for the payload during parenteral administration. The loading efficiencies of NPs have been maximized while the controlled their therapeutic cargos has been released. Theranostic ("treat and see") NPs have developed combining therapy with imaging capabilities to provide real-time, image-guided monitoring of the delivery of their therapeutic payloads. All of these NP accomplishments have been applied to the nanotherapy of late-stage CaP, offering a new opportunity for a previously dismal prognosis. This article gives an update on current developments in the use of nanotechnology for treating late-stage, castration-resistant CaP.

Osteoporosis is a bone incapacitating malady which globally accounts for over hundred million fractures annually. Therapeutic interventions for management of osteoporosis are divided as antiresorptive agents and osteoanabolic agents. Teriparatide is the only osteoana-bolic peptide which is available world-wide for the treatment of osteoporosis. It is administered as a daily subcutaneous injection for the treatment of osteoporosis which results in both poor patient compliance and increase in the cost of the therapy. Even after 20 years of clinical use of teriparatide, no formulation of teriparatide has yet been translated from lab to clinic which can be delivered by non-invasive route The present review critically discusses attempts made by the researchers for efficient delivery of teriparatide through various non-invasive routes such as oral, nasal, pulmonary, and transdermal route. It also discusses long-acting injectable formulations of teriparatide to improve patient compliance. Understanding on the pharmacology of teriparatide highlights the enhanced effectiveness of intermittent/pulsatile mode of teriparatide delivery which has also been elaborated. In addition, targeted delivery of teriparatide using different bone specific targeting moieties has been also discussed.

Macrophages are immuno cells with high flexibility among hematopoietic system. Macrophages are tangled with many diseases like chronic inflammatory, atherosclerosis, autoimmune, and cancer. Macrophages play a major role in developing the inflammation and meanwhile resolving the damage occurred during these disease conditions. Therefore, the use of macrophages in targeted drug delivery appeared to be a promising approach in modifying the microenvironment of inflammatory diseases. The macrophages with cellular backpacks loaded with drugs were appeared to be the effective drug transporter to the brain inflammation. Till date, among the different carrier systems emerged among macrophage targeting: liposomes, microspheres, nanoparticles, and dendrimers were extensively studied. The physicochemical properties like components, lipophilicity, hydrophilicity, ligand presence, and concentration of these carriers may vary the efficacy and specificity of drug targeting to macrophages. The present review provides an insight into M1 and M2 macrophages characteristics, mainly discussed the role of macrophages in regulating several inflammatory diseases. This article underlines the current status and application of different carriers for targeted drug delivery to macrophages along with their efficacy and specificity. In general, the targeted drug delivery was achieved using the carrier systems by removing the intrinsic pathway and bio protection which is offered to the therapeutic molecules. Further, the review also summarizes the newer approaches for macrophage targeting with a brief overview on recent advances and future prospects.

Quality by design (QbD) has recently fascinated researchers for utilizing it in various arenas of pharma trends. By overcoming the conventional process, QbD prevents the risk of errors caused by the 'guess and by god approach'. This framework fosters profound knowledge of product and process quality by implying sound science and risk assessment strategies. The virtue of QbD leads to the collaborative contribution to pharmaceutical industrialists and satisfies the regulatory bodies. Additionally, leading to rapid production, saves time and expenditure, tremendous versatility, provides immense knowledge, improves robustness, higher consistency, reduces user's dilemma, decreases certainty of failure, declining inter-batch variation in pharmaceutical development. In this ever-increasing continuous production world, regulatory organizations such as the U.S. Food & Drug Administration and the International Conference on Harmonization recommend Q8 to Q14 guidelines in order to obtain the desired quality product. This review extensively discusses on various approaches of QbD for the pharmaceutical development of nano-carrier drug delivery systems. Additionally, QbD's applications in process and analytical method development techniques are documented.

Anti-cancer drugs are mostly limited in their use due to poor physicochemical and biopharmaceutical properties. Their lower solubility is the most common hurdle limiting their use upto their potential. In the recent years, the cyclodextrin (CD) complexation have emerged as existing approach to overcome the problem of poor solubility. CD-based nano-technological approaches are safe, stable and showed well in vivo tolerance and greater payload for encapsulation of hydrophobic drugs for the targeted delivery. They are generally chosen due to their ability to get self-assembled to form liposomes, nanoparticles, micelles and nano-sponges etc. This review paper describes a birds-eye view of the various CD-based nano-technological approaches applied for the delivery of anti-cancer moieties to the desired target such as CD based liposomes, niosomes, niosoponges, micelles, nanoparticles, monoclonal antibody, magnetic nanoparticles, small interfering RNA, nanorods, miscellaneous formulation of anti-cancer drugs containing CD. Moreover, the author also summarizes the various shortcomings of such a system and their way ahead.

Most of the oral drug delivery systems demand better retention of drug in the gastrointestinal tract (GIT) for better bioavailability. One of the tools for better gastric retention of the drug is to administer it as a floating drug delivery system (FDDS) by reducing its density, compared to the gastric fluids. This system is helpful to overcome the problems associated with the conventional pharmaceutical dosage forms. The present work is an effort to systematically review the latest advancements in FDDS with a major spotlight on how these systems act to make the dosage form float in the gastric fluid for the slow release, better gastric retention, and improved bioavailability of the orally administered drug. As managing diseases through medicines is going in a new age in which innovative delivery system is being used as well as made accessible for remedial use. The excipients used for making such oral gastro-retention dosage forms (GRDF) to provide sustained release profile of drugs along with the work done so far by different scientists in the past two decades; the patents filed in this area; the evaluation methods for checking the quality of FDDS; and their applications are the major highlights of this work.